---
schema_version: "secwatch.filing_event.v1"
accession: "0001802768-26-000008"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:51:40.406425+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q1 Portfolio Receipts +10% to $925M; raises FY 2026 guidance

## Summary
- Royalty Receipts grew 13% to $887M; driven by Tremfya (+79%), Voranigo (+140%), Evrysdi (+51%).
- Adjusted EBITDA non-GAAP $889M (+21% YoY); Portfolio Cash Flow $722M (+18%).
- Full-year 2026 Portfolio Receipts guidance raised to $3,325M-$3,450M (prev. $3,275M-$3,425M).
- Announced up to $1.25B in royalty transactions; $528M capital deployed in Q1.
- Recorded $69M non-cash impairment on Tazverik; positive Phase 3 data for daraxonrasib and Myqorzo.

## SEC filing metadata
- accession: 0001802768-26-000008
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/0001802768-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001802768-26-000008
- JSON: https://secwatch.observer/filing/0001802768-26-000008.json
- Plain text: https://secwatch.observer/filing/0001802768-26-000008.txt

## Source-grounded claims
- claim_id: deff93e7b103bd5a3c412727f48b4b8a6f99c929
  claim: Royalty Pharma plc reported first quarter of 2026 results: revenue $925 million. Guidance raised.
  evidence_excerpt: Press Release May 6, 2026 R oyalty Pharma reports first quarter 2026 results Portfolio Rece ipts growth o f 10% to $925 million ; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/0001802768-26-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.